Version history

{
  "session_id": "sess_SDA-BIOMNI-GENE_COE-55fc5237",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "mini-max",
  "action": "support",
  "content": "\n\n# Practical Feasibility Assessment: Remaining Hypothesis\n\n## Hypothesis 2: Exosome-Mediated Tau Spreading Module\n\n### Druggability Assessment\n\n| Target Category | Feasibility | Notes |\n|----------------|-------------|-------|\n| Exosome biogenesis (ALIX, ESCRT-III) | **Moderate** | Broad physiological roles create selectivity risk |\n| Exosome surface proteins (tetraspanins, integrins) | **Moderate-High** | Accessible extracellular targets; monoclonal antibodies viable |\n| Tau-exosome loading (sumoylation, kinases) | **Low** | Multiple redundancy in loading pathways |\n|Recipient neuron uptake (LDL receptor family) | **Moderate** | Several candidates (LRP1, LDLR); receptor antagonists feasible |\n| Brain penetration required | **Major hurdle** | Most large-molecule approaches cannot cross BBB |\n\n**Druggability Score: 4/10**\nThe extracellular nature of exosome signaling is accessible, but intracellular steps in loading/export are poorly tractable with current modalities.\n\n---\n\n### Existing Compounds & Clinical Trials\n\n**Active programs (2024 landscape):**\n\n- **Anti-exosome antibodies** (e.g., tetraspanin-8 targeting): Preclinical; no IND filings identified\n- **GW4869** (nSMase2 inhibitor): Widely used in vitro; off-target toxicity; poor PK; not BBB-penetrant\n- **Rab27a knockdown**: Validated in mouse models; siRNA delivery to neurons remains unsolved\n- **Tau-targeted antibodies** (not exosome-specific): Several Phase II failures (semorinemab, gosuranemab) — targeting extracellular tau, not exosome-mediated spreading specifically\n\n**No clinical-stage programs specifically targeting exosome-mediated spreading exist.** The field is precompetitive and pre-IND.\n\n---\n\n### Development Cost & Timeline\n\n| Phase | Estimated Cost | Timeline |\n|-------|---------------|----------|\n| Target validation (in vitro) | $2–4M | 18–24 months |\n| Lead optimization (BBB-penetrant small molecules or biologics) | $15–30M | 3–5 years |\n| IND-enabling toxicology | $5–8M | 12–18 months |\n| Phase I (first-in-human) | $10–15M | 2 years |\n\n**Total to Phase I: ~$35–60M over 7–9 years minimum.**\n\nRealistic risk: Exosome biology is not disease-specific enough; candidate hits will likely affect physiological exosome trafficking (immune surveillance, synaptic function), creating unacceptable safety signals.\n\n---\n\n### Safety Concerns\n\n**Critical concerns:**\n- Exosomes mediate CNS immune surveillance; blocking biogenesis could impair microglial function and debris clearance\n- Tetraspanin inhibition would affect platelet aggregation, wound healing, and immune cell trafficking\n- LRP1 knockouts in mice show embryonic lethality and cognitive deficits — systemic inhibition is likely toxic\n- Off-target effects in peripheral organs (liver, kidney) given high exosome production outside CNS\n\n**BBB penetration adds complexity:** AAV-mediated gene therapy could target neuronal exosome production but requires invasive CNS delivery.\n\n---\n\n### Overall Feasibility Score: **0.35**\n\n**Rationale**: Target is mechanistically plausible but poorly druggable with current modalities. The field lacks validated pharmacologic agents. Safety liabilities from broadly disrupting exosome biology are substantial. Even if target is validated, 7–9 years to first-in-human with no Phase I-ready compound is a significant investment with low probability of success.\n\n**Recommendation**: Deprioritize unless parallel efforts (single-cell resolution, biomarker validation) demonstrate that exosome-mediated spreading is specifically operative in human AD versus other tauopathies. Comparative PD/FTD data is essential before further investment.",
  "tokens_used": "906"
}